PDF(Pubmed)
Abstract：
UNASSIGNED: In this study, we aimed to investigate the prognostic value of programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), and programmed cell death ligand 2 (PD-L2) expressions on immune and cancer cells in terms of survival in patients with lung adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
UNASSIGNED: Between January 2000 and December 2012, a total of 191 patients (172 males, 19 females; mean age: 60.3±8.4 years; range, 38 to 78 years) who were diagnosed with non-small cell lung cancer and underwent anatomic resection and mediastinal lymph node dissection were retrospectively analyzed. The patients were evaluated in three groups including lung squamous cell carcinoma (n=61), adenocarcinoma (n=66), and large-cell carcinoma (n=64). The survival rates of all three groups were compared in terms of immunohistochemical expression levels of PD-1, PD-L1, and PD-L2.
UNASSIGNED: The mean follow-up was 71.8±47.9 months. In all histological subtypes, PD-1 expressions on tumor and immune cells were observed in 33% (61/191) and in 53.1% (102/191) of the patients, respectively. Higher expression levels of PD-L1 and PD-L2 at any intensity on tumor and immune cells were defined only in lung adenocarcinomas, and PD-L1 and PD-L2 values were detected in 36.4% (22/64) of these patients. The PD-L1 expressions on tumor and immune cells were observed in 41.7% (10/24) and 25% (6/24) of the patients, respectively. The PD-L2 expressions on tumor and immune cells were detected in 16.7% (4/24) and 8.4% (2/24) of the patients, respectively. Univariate and multivariate analyses revealed that PD-1 expression in tumor cells was an independent prognostic factor in all histological subtypes.
UNASSIGNED: Our study results suggest that PD-1 expression is a poor prognostic factor for overall survival in patients with completely resected adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
UNASSIGNED: Between January 2000 and December 2012, a total of 191 patients (172 males, 19 females; mean age: 60.3±8.4 years; range, 38 to 78 years) who were diagnosed with non-small cell lung cancer and underwent anatomic resection and mediastinal lymph node dissection were retrospectively analyzed. The patients were evaluated in three groups including lung squamous cell carcinoma (n=61), adenocarcinoma (n=66), and large-cell carcinoma (n=64). The survival rates of all three groups were compared in terms of immunohistochemical expression levels of PD-1, PD-L1, and PD-L2.
UNASSIGNED: The mean follow-up was 71.8±47.9 months. In all histological subtypes, PD-1 expressions on tumor and immune cells were observed in 33% (61/191) and in 53.1% (102/191) of the patients, respectively. Higher expression levels of PD-L1 and PD-L2 at any intensity on tumor and immune cells were defined only in lung adenocarcinomas, and PD-L1 and PD-L2 values were detected in 36.4% (22/64) of these patients. The PD-L1 expressions on tumor and immune cells were observed in 41.7% (10/24) and 25% (6/24) of the patients, respectively. The PD-L2 expressions on tumor and immune cells were detected in 16.7% (4/24) and 8.4% (2/24) of the patients, respectively. Univariate and multivariate analyses revealed that PD-1 expression in tumor cells was an independent prognostic factor in all histological subtypes.
UNASSIGNED: Our study results suggest that PD-1 expression is a poor prognostic factor for overall survival in patients with completely resected adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
摘要：
■在这项研究中，我们旨在研究程序性细胞死亡蛋白1（PD-1）的预后价值，程序性细胞死亡配体1（PD-L1），和程序性细胞死亡配体2（PD-L2）在免疫和癌细胞上的表达，鳞状细胞癌,和大细胞癌.
■在2000年1月至2012年12月之间，共有191名患者（172名男性，19名女性；平均年龄：60.3±8.4岁；范围，回顾性分析38至78岁）诊断为非小细胞肺癌并进行解剖切除和纵隔淋巴结清扫的患者。将患者分为三组，包括肺鳞状细胞癌（n=61），腺癌（n=66），和大细胞癌（n=64）。根据PD-1，PD-L1和PD-L2的免疫组织化学表达水平比较所有三组的生存率。
■平均随访时间为71.8±47.9个月。在所有组织学亚型中，在33%(61/191)和53.1%(102/191)的患者中观察到PD-1在肿瘤和免疫细胞上的表达,分别。任何强度的PD-L1和PD-L2在肿瘤和免疫细胞上的较高表达水平仅在肺腺癌中定义。在这些患者中，有36.4％（22/64）检测到PD-L1和PD-L2值。在41.7%(10/24)和25%(6/24)的患者中观察到PD-L1在肿瘤和免疫细胞上的表达,分别。在16.7%(4/24)和8.4%(2/24)的患者中检测到PD-L2在肿瘤和免疫细胞上的表达,分别。单变量和多变量分析显示，肿瘤细胞中PD-1的表达是所有组织学亚型的独立预后因素。
■我们的研究结果表明，PD-1表达是腺癌完全切除患者总生存期的不良预后因素，鳞状细胞癌,和大细胞癌.
■在2000年1月至2012年12月之间，共有191名患者（172名男性，19名女性；平均年龄：60.3±8.4岁；范围，回顾性分析38至78岁）诊断为非小细胞肺癌并进行解剖切除和纵隔淋巴结清扫的患者。将患者分为三组，包括肺鳞状细胞癌（n=61），腺癌（n=66），和大细胞癌（n=64）。根据PD-1，PD-L1和PD-L2的免疫组织化学表达水平比较所有三组的生存率。
■平均随访时间为71.8±47.9个月。在所有组织学亚型中，在33%(61/191)和53.1%(102/191)的患者中观察到PD-1在肿瘤和免疫细胞上的表达,分别。任何强度的PD-L1和PD-L2在肿瘤和免疫细胞上的较高表达水平仅在肺腺癌中定义。在这些患者中，有36.4％（22/64）检测到PD-L1和PD-L2值。在41.7%(10/24)和25%(6/24)的患者中观察到PD-L1在肿瘤和免疫细胞上的表达,分别。在16.7%(4/24)和8.4%(2/24)的患者中检测到PD-L2在肿瘤和免疫细胞上的表达,分别。单变量和多变量分析显示，肿瘤细胞中PD-1的表达是所有组织学亚型的独立预后因素。
■我们的研究结果表明，PD-1表达是腺癌完全切除患者总生存期的不良预后因素，鳞状细胞癌,和大细胞癌.
